Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...

Bharat Biotech's oral cholera vaccine, Hillchol, has demonstrated successful Phase III clinical trial results, proving ...

Bharat Biotech to launch Hillchol, its oral cholera vaccine, amid a global shortage. With Phase III trials completed and 200M ...

The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ) has provided an update. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Bharat Biotech's Hillchol OCV, effective against cholera serotypes, aims to provide affordable, accessible vaccines for ...

New Orleans biotech South Rampart Pharma advances non-opioid pain drug with $8M funding from Ochsner Ventures and Gulf South ...

Bharat Biotech International Ltd on Wednesday said its oral Cholera Vaccine Hillchol has successfully completed phase III ...

Finance Income, net was $1.0 million for the three months ended March 31, 2025, compared to $0.7 million in the same period ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Satsuma, a unit of a Japanese drugmaker with U.S. headquarters in Durham, said its treatment, called Atzumi, received its new ...